Use of Acitretin Among Girls and Women of Childbearing Age and Occurrence of Acitretin-Exposed Pregnancies in Germany.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
accepted:
02
10
2023
medline:
9
11
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
ppublish
Résumé
Acitretin has long-lasting teratogenic properties. Therefore, pregnancies must be avoided during and within 3 years after acitretin treatment. We aimed to describe (i) acitretin use in women of childbearing age in Germany, (ii) the occurrence of acitretin-exposed pregnancies, and (iii) malformations among children exposed in utero. Using 2004-2019 data from the German Pharmacoepidemiological Research Database (GePaRD-claims data from ~ 20% of the German population), we determined annual age-standardized prevalence of acitretin use among girls and women aged 13-49 years. In longitudinal analyses, we estimated the number of exposed pregnancies by assessing whether the exposure window assigned to the last dispensation before pregnancy (days covered by dispensation plus 3 years) overlapped the onset of pregnancy or whether there was a dispensation in the first eight weeks of pregnancy. Data of live-born children with in utero exposure to acitretin were reviewed to assess the presence of congenital malformations. The age-standardized prevalence of acitretin use per 1000 girls and women was 0.04 in 2019. We identified 35 acitretin-exposed pregnancies; 94.3% of these pregnancies were classified as exposed because they occurred within 3 years after stopping acitretin treatment. Among 18 live-born children linked to their mother, four children (22.2%) had congenital malformations (three children with a major malformation). We observed 35 acitretin-exposed pregnancies mainly because treatment ended too late before pregnancy. Approximately one in five children born from these pregnancies had malformations, highlighting the importance of drawing more attention to the long-lasting teratogenicity of this drug.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Acitretin has long-lasting teratogenic properties. Therefore, pregnancies must be avoided during and within 3 years after acitretin treatment. We aimed to describe (i) acitretin use in women of childbearing age in Germany, (ii) the occurrence of acitretin-exposed pregnancies, and (iii) malformations among children exposed in utero.
METHODS
METHODS
Using 2004-2019 data from the German Pharmacoepidemiological Research Database (GePaRD-claims data from ~ 20% of the German population), we determined annual age-standardized prevalence of acitretin use among girls and women aged 13-49 years. In longitudinal analyses, we estimated the number of exposed pregnancies by assessing whether the exposure window assigned to the last dispensation before pregnancy (days covered by dispensation plus 3 years) overlapped the onset of pregnancy or whether there was a dispensation in the first eight weeks of pregnancy. Data of live-born children with in utero exposure to acitretin were reviewed to assess the presence of congenital malformations.
RESULTS
RESULTS
The age-standardized prevalence of acitretin use per 1000 girls and women was 0.04 in 2019. We identified 35 acitretin-exposed pregnancies; 94.3% of these pregnancies were classified as exposed because they occurred within 3 years after stopping acitretin treatment. Among 18 live-born children linked to their mother, four children (22.2%) had congenital malformations (three children with a major malformation).
CONCLUSIONS
CONCLUSIONS
We observed 35 acitretin-exposed pregnancies mainly because treatment ended too late before pregnancy. Approximately one in five children born from these pregnancies had malformations, highlighting the importance of drawing more attention to the long-lasting teratogenicity of this drug.
Identifiants
pubmed: 37906397
doi: 10.1007/s40261-023-01314-2
pii: 10.1007/s40261-023-01314-2
pmc: PMC10632260
doi:
Substances chimiques
Acitretin
LCH760E9T7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
865-872Subventions
Organisme : Bundesinstitut für Arzneimittel und Medizinprodukte
ID : V-18281/ 68605 / 2019-2020
Informations de copyright
© 2023. The Author(s).
Références
Clin Drug Investig. 2023 Feb;43(2):109-117
pubmed: 36542272
Front Public Health. 2020 Aug 12;8:350
pubmed: 32903398
Mult Scler Relat Disord. 2022 Nov;67:104184
pubmed: 36174258
Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):258-64
pubmed: 21351307
Pharmacoepidemiol Drug Saf. 2015 May;24(5):526-33
pubmed: 25753265
Pharmacoepidemiol Drug Saf. 2018 Sep;27(9):1005-1010
pubmed: 30022557
J Dtsch Dermatol Ges. 2021 Jun;19(6):934-951
pubmed: 34139080
Dtsch Med Wochenschr. 1984 Sep 28;109(39):1476-80
pubmed: 6479047
Birth Defects Res A Clin Mol Teratol. 2004 Oct;70(10):831-3
pubmed: 15470719
Br J Dermatol. 2021 Feb;184(2):243-258
pubmed: 32358790
Pharmacoepidemiol Drug Saf. 2023 Feb;32(2):148-157
pubmed: 36401747
Drugs. 1992 Apr;43(4):597-627
pubmed: 1377120
Teratology. 1995 Oct;52(4):215-9
pubmed: 8838291
J Drugs Dermatol. 2013 Jul 1;12(7):799-802
pubmed: 23884494
Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):873-80
pubmed: 23733705
Dermatology. 1994;189(2):109-16
pubmed: 8075435
Stud Fam Plann. 2014 Sep;45(3):301-14
pubmed: 25207494